SAN MATEO, California, April 27, 2026, 13:03 PDT
- Sagimet set its offering at $6 per share, moving 29.17 million shares to target roughly $175 million in proceeds.
- The company intends to bankroll a U.S. Phase 3 acne trial for denifanstat and keep its acne programs running through 2028.
- Sagimet’s MASH liver-disease program won’t move forward for now; unless the company lands non-dilutive funding, it’s been pushed to the back burner.
Sagimet Biosciences Inc. shares surged Monday, after the company set terms for a $175 million stock sale and signaled plans to funnel proceeds into a pivotal U.S. acne study for denifanstat—dermatology now takes priority in its pipeline. Sagimet is offering 29,166,700 Series A common shares at $6 each, targeting a closing date near April 28.
Timing is key here: Sagimet, still in the clinic stage, needs to bankroll an expanded and pricier Phase 3—long before any sales come in. The company expects proceeds from the offering, plus the cash already on hand, will keep its acne programs funded until 2028 and carry them to the planned Phase 3 results for moderate to severe acne.
Shares jumped roughly 38% to $8.12 in Monday afternoon trading, after the stock hit an intraday peak of $9.34. Volume surged past 48 million shares.
Sagimet is targeting mid-2026 to submit an Investigational New Drug application for denifanstat in acne—this is the key FDA green light to move a drug into patient studies in the U.S. The company has its sights set on launching a registrational Phase 3 trial in the back half of 2026, assuming it gets the IND go-ahead.
Chief Executive David Happel said the company is moving ahead with plans to “advance denifanstat in acne for the U.S.” after its license partner Ascletis Bioscience pulled off a successful Phase 3 trial in China. That study included 240 patients, according to Sagimet, and showed that once-daily 50 mg denifanstat was generally well tolerated after 52 weeks. Sagimet Biosciences Inc.
Denifanstat targets fatty acid synthase, or FASN, the enzyme responsible for fat production. Sagimet claims that blocking FASN could lower sebum—the oily substance tied to acne flare-ups—and also tackle inflammation in the skin.
Sagimet is footing the bill for TVB-3567, a second FASN inhibitor, through Phase 2 topline data, and aims to push a topical FASN candidate toward an IND filing. “We’re prioritizing our dermatology franchise,” CFO Thierry Chauche said, adding the company will look for non-dilutive capital to support its MASH program. Sagimet Biosciences Inc.
Still, that path looks pretty tight. The U.S. acne trial is hanging on FDA clearance, and approval for the drug in the United States hasn’t happened. Yes, the stock sale gives Sagimet a longer cash runway and investors seemed to like that, but existing shareholders take a dilution hit. Sagimet said it’s pausing further clinical work in MASH, though, unless it finds non-dilutive funding—that is, money that doesn’t mean selling more shares.
Sagimet, in a recent filing, pegged its cash, cash equivalents and marketable securities at roughly $104.5 million as of March 31. That figure, the company noted, is preliminary and hasn’t been audited. The tally came ahead of the new offering.
The MASH pause resets the short-term competitive landscape. Madrigal Pharmaceuticals’ Rezdiffra, or resmetirom, picked up accelerated U.S. approval in 2024 as the first therapy for NASH—now called MASH—with moderate to advanced fibrosis. After that, Novo Nordisk’s Wegovy landed as the first GLP-1 to get the nod for MASH.
Sagimet isn’t betting on denifanstat alone for MASH; the current focus is pairing it with resmetirom. Phase 1 pharmacokinetics wrapped up in December 2025. The company says that, with adequate funding, the combo could head into Phase 2 as soon as the back half of 2026.
Leerink Partners, TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are taking the lead as joint bookrunners for the stock sale. Canaccord Genuity, H.C. Wainwright & Co., and Jones step in as co-lead managers.
